The Methods section on the various analyses performed in the Methods section and their outcomes is not easily understood by those of us who are not statisticians or methodologists. Please can some extra explanation be included for the reader of the article.
On the same theme, please can the sections on "running the Model' and 'Probabilistic Analysis' be written with this in mind.
Results
In the results section, the narrative for each of the figures need to be clearly put. I am not sure that Figure 4 adds anything.
The Discussion In the paper by Livingston et al. Experimental and Clinical Endocrinology & Diabetes 2015; 123(10) :594-597 · it was stated that 8 out of 26106 cases would not have ben identified had the strategy of T4 + TSH not been applied. While their evaluation did not have the weight of analysis in this study, it would be reasonable to include this paper in the discussion. The conclusions of that paper were different for the paper under review here. Please can this paper be cited with a reflection from the authors.
While the economic analysis that has been carried out is robust, it does not take account of the importance of assessing each individual in terms of the reason for requesting the test. It is essential that UK GPs always have the opportunity to request T4 and even T3 when a patient presents with ? thyrotoxicosis, if this will enable better discrimination and more effective decision making in terms of thyroid hormone status. 
REVIEWER

GENERAL COMMENTS
The question is clinically relevant. As eluded to in the Introduction, many jurisdictions already support initial isolated TSH testing for thyroid function assessment on the assumption that this is an effective (and likely cost-effective) approach. Most if not all of the studies analysing costs and strategies of thyroid function testing are very old and don't use modern cost-effectiveness methodologies. I also note that NICE are currently examining thyroid disease and that this study's question will be examined in that guideline.
The methods are detailed logically. Some of the estimates for model inputs may be way off (GP recognition of hypopituitarism, as it probably occurs secondary hypothyroidism diagnosed because pituitary disease is diagnosed first; and costs and utilities of hypopituitarism), but I acknowledge they were reasonable guesses and the final results of cost-effectiveness or otherwise are not sensitive to them.
The results are clear-cut and discussion is reasonable. This paper is an important piece of analysis in the matter of what is a reasonable approach to thyroid function testing in 1ry care -this often being a 'push button' approach in 1ry care as sometimes in 2ry care.
VERSION 1 -AUTHOR RESPONSE
• We thank the reviewer for this view of paper.
Points to be addressed:
• Not everyone knows what a Markov chain is. Please can this be explained. (10):594-597 · it was stated that 8 out of 26106 cases would not have ben identified had the strategy of T4 + TSH not been applied. While their evaluation did not have the weight of analysis in this study, it would be reasonable to include this paper in the discussion. The conclusions of that paper were different for the paper under review here. Please can this paper be cited with a reflection from the authors.
-
We have done this.
• While the economic analysis that has been carried out is robust, it does not take account of the importance of assessing each individual in terms of the reason for requesting the test. It is essential that UK GPs always have the opportunity to request T4 and even T3 when a patient presents with ? thyrotoxicosis, if this will enable better discrimination and more effective decision making in terms of thyroid hormone status.
We agree, although in nearly every instance, a policy of TSH as a front-line test with reflex testing of FT4 and FT3 is sufficient. In this report, Brian Shine and colleagues, examine the benefits of measuring FT4 along with TSH in all routine requests for thyroid function tests in primary care. The authors have used a Markov model to show an incremental cost effectiveness ratio (ICER) of £71,437 which was largely driven by the utilities of the treated hypopituitary state, the likelihood of going to the GP, and the GP recognising a hypopituitary patient. This is an interesting analysis of potential relevance for routine thyroid testing in the UK. However, the model is based on several generalisations which may not necessarily reflect everyday practice. My specific comments are as follows.
• A proportion of thyroid function requests in primary care is undertaken in individuals with preexisting thyroid disease for the purpose of monitoring. Most of such tests are in patients with hypothyroidism, for whom a TSH only strategy will suffice. In addition, thyroid tests are also frequently requested for patients with hyperthyroidism or pregnant patients, for whom FT4 must be measured as of necessity. So, the TSH only versus TSH/FT4 approach will only be relevant where a diagnosis is sought in patients without pre-existing thyroid dysfunction. This should be considered in the incidence projections of thyroid testing and the model should be revised accordingly to exclude thyroid function tests done for individuals with pre-existing thyroid disease or tests undertaken in pregnancy using estimates of thyroid disease prevalence in the population.
We have considered this, but people with pre-existing thyroid disease are at the same risk of developing pituitary disease.
• On page 4, under Clinical Background, please include a sentence or two on how hypopituitarism is managed taking into account the various potential causes of hypopituitarism.
We have done this
• Table 1: in table 1 , you should include a sensitivity range as well as the reference or sources for the probabilities quoted.
We have included references, but are not sure how to include a senstivity range.
• Table 1 : which of these probabilities are based on assumption? If so, this should be stated as such in the table. In the text, the process of arriving at these assumptions should be clarified. Was this based on the expertise of the authors alone or did they consult more widely.
• Page 6, under costs: the costs outlined in this section should be itemised and tabulated with references or sources provided for the quoted costs.
This is done in a new Table 2. • Page 5, line 42: it is stated that GPs perform thyroid tests on 15.7% of the population. The cited study (reference 6) reports that thyroid tests were done in 12% of the population after excluding patients with thyroid disease. The present analysis should be based on tests undertaken in individuals without known or pre-existing thyroid disease.
As we pointed out above, people with thyroid disorders are at the same risk of developing pituitary disease as the rest of the population, and therefore should be included -
The figures are not labelled creating some confusion between figures 3 and 4.
• We have removed The question is clinically relevant. As eluded to in the Introduction, many jurisdictions already support initial isolated TSH testing for thyroid function assessment on the assumption that this is an effective (and likely cost-effective) approach. Most if not all of the studies analysing costs and strategies of thyroid function testing are very old and don't use modern cost-effectiveness methodologies. I also note that NICE are currently examining thyroid disease and that this study's question will be examined in that guideline.
We thank the reviewer for this. We have examined the papers that NICE has released to the public, and could not find that this guideline will address this problem.
•
Perversely, the worse a GP's clinical acumen, the better the ICER! However, this is not the biggest driver for the ICER
•
The results are clear-cut and discussion is reasonable. 
